Korsana Biosciences, Inc. Common Stock
KRSA
65 hedge funds and large institutions have $96M invested in Korsana Biosciences, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 20 closing their positions.
166% more call options, than puts
Call options by funds: $2.07M | Put options by funds: $779K
54% more capital invested
Capital invested by funds: $62.5M → $96M (+$33.5M)
4.86% less ownership
Funds ownership: 65.76% → 60.9% (-4.9%)
6% less funds holding
Funds holding: 69 → 65 (-4)
20% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 20
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$430K |
| 2 |
MP
MFN Partners
Boston,
Massachusetts
|
+$430K |
| 3 |
SPC
Slate Path Capital
New York
|
+$430K |
| 4 |
PVI
Pura Vida Investments
New York
|
+$227K |
| 5 |
Millennium Management
New York
|
+$174K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$559K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$553K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$345K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$334K |
| 5 |
DC
Davenport & Co
Richmond,
Virginia
|
-$236K |
KRSA Hedge Fund Activity: Q2 2021 in Review
65 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q2 2021, worth a combined $96M — up 54% from $62.5M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of KRSA and 16 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 15 added.
The largest buyer was Artal Group, adding an estimated $430K. The largest seller was BlackRock, cutting an estimated $559K.
- 65 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q2 2021, down from 69 in Q1 2021.
- Funds reported $96M of Korsana Biosciences, Inc. Common Stock stock for Q2 2021, up 54% quarter-over-quarter.
- 16 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q2 2021 and 20 closed out, a net change of -4 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q2 2021 was Artal Group, an estimated $430K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q2 2021 was BlackRock, an estimated $559K sold.
Based on aggregated 13F filings for Q2 2021.